Prometax (rivastigmine)
- Region
- 🇪🇺 EU
- Active substance
- rivastigmine
- Company
- Almirall, S.A.
- Status
- Authorised
- Therapeutic area
- Alzheimer Disease; Parkinson Disease; Dementia
- CHMP opinion
- Wed 16 Sep 1998
- EU approval
- Fri 04 Dec 1998
- Application
- EMEA/H/C/000255
- ATC
- N06DA03
- Official record
- www.ema.europa.eu
Indication
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Rivastigmine Hexal Authorised · Hexal AG
- 🇪🇺 Rivastigmine Sandoz Authorised · Sandoz GmbH
- 🇪🇺 Rivastigmine 1 A Pharma Authorised · 1 A Pharma GmbH
- 🇪🇺 Exelon Authorised · Novartis Europharm Limited
- 🇪🇺 Nimvastid Authorised · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 Rivastigmine Actavis Authorised · Actavis Group PTC ehf
- 🇪🇺 Rivastigmine 3M Health Care Ltd Withdrawn · 3M Health Care Limited
- 🇪🇺 Rivastigmine Teva Withdrawn · Teva Pharma B.V.
Follow Prometax
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.